Network origin in Frances Wildhaber first degree
Entity | Entity type | Industry | |
---|---|---|---|
Novartis Venture Funds
Novartis Venture Funds Investment ManagersFinance Novartis Venture Funds (NVF) is a venture capital firm with headquarters in Basel, Switzerland and an additional office in Cambridge, MA. The firm was founded in 1996. NVF is a subsidiary of Novartis AG (VX: NOVN) and was created following the 1996 merger of Ciba-Geigy and Sandoz.
2
| Subsidiary | Investment Managers | 2 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Frances Wildhaber via their personal network
Company | Sector | Related people | Main position |
---|---|---|---|
Okairos AG
Okairos AG Pharmaceuticals: MajorHealth Technology Okairos AG develops preventive and therapeutic vaccines against human chronic infectious diseases. Its products include genetic vaccines, adenovirus vector platform, and proprietary cell line. The company was founded by Riccardo Cortese, Alfredo Nicosia, and Antonella Folgori in 2007 and is headquartered in Basel, Switzerland. | Pharmaceuticals: Major | Director/Board Member | |
Covagen AG
Covagen AG BiotechnologyHealth Technology Covagen AG engages in the research in as well as development, production, and distribution of pharmaceutical and diagnostic products and technologies. The company was founded by Julian Bertschinger and Dragan Grabulovski in 2007 and is headquartered in Zug, Switzerland. | Biotechnology | Director/Board Member | |
Imcheck Therapeutics SAS
Imcheck Therapeutics SAS Pharmaceuticals: MajorHealth Technology Imcheck Therapeutics SAS operates as a biopharmaceutical company which develops immunotherapeutic anti-cancer strategies for research. The company was founded by Olive Daniel in 2015 and is headquartered in Marseille, France. | Pharmaceuticals: Major | Director/Board Member | |
Priothera SAS
Priothera SAS BiotechnologyHealth Technology Part of Priothera Ltd., Priothera SAS is a French company dedicated to improving the lives of patients suffering from hematological malignancies by delivering an innovative immune modulator to enhance the curative potential of both allogeneic hematopoietic stem cell transplantation (HSCT) and CAR-T cell therapy. The company is based in Saint-Louis, France. Priothera is leading the way in developing Mocravimod, a S1P receptor modulator as an adjunctive and maintenance immune therapy to allo-HSCT and to CAR-T. Mocravimod has the potential to reduce the occurrence of (acute) GVHD without suppressing T cell function, thus GVL is maintained. Priothera is developing Mocravimod (KRP203) to significantly improve the clinical outcome of allo-HSCT and CAR-T therapy. The company was founded in 2020 by Philippe Lievre, Florent Gros, Brice R. Suire, Stephan Oehen, Simone Seiter. Florent Gros has been the CEO since 2020. | Biotechnology | Chief Executive Officer | |
Cornell University
Cornell University Other Consumer ServicesConsumer Services Cornell University is an educational institution that offers undergraduate and post graduate programs. It was founded in 1865 and is based in Ithaca, NY. | College/University | Doctorate Degree | |
McKinsey & Co., Inc.
McKinsey & Co., Inc. Miscellaneous Commercial ServicesCommercial Services McKinsey & Co., Inc. provides management consulting services. It specializes in design, marketing and sales, analytics, operations, transformation and restructuring, risk, strategy and corporate finance, and sustainability and resource productivity. The company was founded by James O. McKinsey in 1926 and is headquartered in New York, NY. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
PHARMABCINE INC. | Biotechnology | Director/Board Member | |
BICYCLE THERAPEUTICS PLC | Biotechnology | Director/Board Member | |
Heptares Therapeutics Ltd.
Heptares Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Heptares Therapeutics Ltd. designs and develops new medicines targeting G protein-coupled receptors. It builts an exciting discovery and development pipeline of novel drug candidates, which have the potential to transform the treatment of serious diseases, including alzheimer's disease, parkinson's disease, schizophrenia, migraine and diabetes. The company was founded by Richard Henderson, Fiona Hamilton Marshall, Ludwig Michael Steinmetz, Christopher G. Tate and Malcolm Weir in 2007 and is headquartered in Welwyn Garden City, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
Nabriva Therapeutics GmbH
Nabriva Therapeutics GmbH Pharmaceuticals: MajorHealth Technology Nabriva Therapeutics GmbH is a clinical-stage biopharmaceutical company, which engages in the research and development of novel anti-infective agents to treat serious infections. It focuses on the pleuromutilin class of antibiotics. The company was founded by Rodger Novak in October 2005 and is headquartered in Vienna, Austria. | Pharmaceuticals: Major | Director/Board Member | |
Swissvention Partners GmbH | Chief Executive Officer | ||
Oxagen Ltd.
Oxagen Ltd. Pharmaceuticals: MajorHealth Technology Oxagen Ltd. develops novel molecule drugs to treat inflammatory and respiratory diseases. It offers OC000459, an oral CRTH2 antagonist for the treatment of eosinophilic asthma and allergic rhino conjunctivitis. The company was founded by Nick Cross, John Irving Bellin, Mark Edwards, Trevor J. Nicholls and Ian Michael Laing on September 05 1996 and is headquartered in London, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
MerLion Pharmaceuticals Pte Ltd.
MerLion Pharmaceuticals Pte Ltd. Miscellaneous Commercial ServicesCommercial Services MerLion Pharmaceuticals Pte Ltd. provides drug discovery and development services. It focuses on developing its lead antibacterial candidate, finafloxacin, through early and mid-stage clinical trials. The company was founded in 2002 and is headquartered in Singapore. | Miscellaneous Commercial Services | Director/Board Member | |
F2G Ltd.
F2G Ltd. Pharmaceuticals: MajorHealth Technology F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
CUTISS AG
CUTISS AG Medical SpecialtiesHealth Technology CUTISS AG develops bioengineered skin grafts to heal people with skin defects. The company was founded by Ernst Reichmann, Martin Meuli, Daniela Marino, Clemens Schiestl and Fabienne Hartmann-Fritsch and is headquartered in Zurich, Switzerland. | Medical Specialties | Director/Board Member | |
Forendo Pharma Oy
Forendo Pharma Oy Pharmaceuticals: MajorHealth Technology Forendo Pharma Oy provides novel pharmaceutical treatments for endometriosis and low testosterone levels. Its product fispemifene is the first selective estrogen receptor modulator designed only for men, which helps for the treatment of symptoms of low testosterone, in phase II clinical studies in men with secondary hypogonadism; fispemifene has normalized the low testosterone levels. Its 17HSD1-inhibitor focuses on endometriosis, is a potent and selective lead compounds demonstrated in vivo proof of efficacy in disease model of endometriosis. The company was founded by Risto Arvo Sakari Lammintausta in 2013 and is headquartered in Turku, Finland. | Pharmaceuticals: Major | Director/Board Member | |
Ribon Therapeutics, Inc.
Ribon Therapeutics, Inc. BiotechnologyHealth Technology Ribon Therapeutics, Inc. operates as a biotechnology company which focuses on developing therapeutics targeting monoADP-ribosylating PARPs for cancer. Its medicines are used for blocking cancer cells? fundamental survival mechanisms. The company was founded by W. Lee Kraus, Tim Mitchison and Paul Chang in 2015 and is headquartered in Lexington, MA. | Biotechnology | Director/Board Member | |
Arctos Medical AG
Arctos Medical AG BiotechnologyHealth Technology Arctos Medical AG engages in the acquisition, development, holding, registration, management, disposal, and exploitation of intellectual property rights and similar assets in the medical sector. These include patents, trademarks, licenses, industrial property rights, and inventions. The company was founded on June 6, 2012 and is headquartered in Bern, Switzerland. | Biotechnology | Director/Board Member | |
SENSIRION HOLDING AG | Semiconductors | Director/Board Member | |
Swiss National Science Foundation | Corporate Officer/Principal | ||
Amyl Therapeutics SRL
Amyl Therapeutics SRL BiotechnologyHealth Technology Amyl Therapeutics SRL is a Belgian biotech company that uses a novel mechanism to bind to the amyloid fold of toxic protein aggregates of various types, including antibody light chain (AL) or transthyretin (TTR) aggregates, which accumulate in peripheral organs to cause systemic amyloidosis diseases, but also amyloid-? (A?), tau, and ?-synuclein aggregates, which accumulate in the brain to cause Alzheimer's and Parkinson's diseases. Amyl Therapeutics is based in Liege, BE and was founded in November 2020 by Drs. The company's therapies based on the clarity technology platform are designed to prevent the further accumulation of aggregates and clear existing aggregates from the peripheral organs and the brain, while also blocking further cell-to-cell spread of misfolded proteins. Florent Gros and Pierre Vandepapelière. Pierre Vandepapelière has been the CEO since incorporation. | Biotechnology | Founder | |
CAPTOR THERAPEUTICS SPOLKA AKCYJNA | Pharmaceuticals: Major | Director/Board Member | |
Altimmune UK Ltd.
Altimmune UK Ltd. BiotechnologyHealth Technology Altimmune UK Ltd. engages in the discovery and development of prophylactic and therapeutic vaccines against mutating viruses and cancer. It provides T-cell vaccines to protect patients against infectious diseases (most notably mutating viruses) and to treat cancers; and Flunisyn, a DepoVaccine to protect against influenza. The company was founded by Bertrand Georges in 2003 and is headquartered in London, the United Kingdom. | Biotechnology | Director/Board Member | |
École Supérieure de Biothechnologie Strasbourg | College/University | Graduate Degree | |
NEOVACS | Pharmaceuticals: Major | Director/Board Member | |
MyoPowers Medical Technologies France SAS
MyoPowers Medical Technologies France SAS Medical SpecialtiesHealth Technology MyoPowers Medical Technologies France SA operates as a medical device company. It specializes in muscle technologies to restore or improve muscle function. The firm also develops implantable medical devices for the treatment of severe stress urinary incontinence. The company was founded by Piergiorgio Tozzi and Daniel Hyoz in June 2004 and is headquartered in Lausanne, Switzerland. | Medical Specialties | Director/Board Member | |
Cellerix SA
Cellerix SA Pharmaceuticals: GenericHealth Technology Founded in 2004, Cellerix is a biopharmaceutical company that develops innovative treatments based on cell therapy. Cellerix was founded within the Genetrix Group, group of biotechnology companies specialising in biomedicine. The Genetrix Group began its activities in 2001 at the National Centre for Biotechnology (CNB), which belongs to the Spanish Research Council (CSIC). One of the main objectives of Genetrix is to convert basic research results into therapeutic realities. Cellerix is leading the development of a new generation of medicines using expanded adult stem cells from adipose tissue (eASCs). Development is at a clinically advanced stage and the results from clinical trials in Phase I and II have been very promising. Obtaining these eASCs has big advantages because the process makes use of tissue that is almost always discarded from surgical procedures such as liposuction. eASCs have the capacity to activate physiological repair mechanisms through interaction with affected tissue. This technology represents a revolution in the treatment of some diseases that cannot satisfactorily be cured at present. Cellerix is working actively to adapt this new therapeutic strategy to treat autoimmune diseases such as inflammatory bowel disease. The main goal of the company is to market new tools for treating these diseases, which have a considerable negative impact of the quality of life of the sufferers. Cellerix also researches and develops medicines in other areas such as the development of skin equivalents, which are initially intended for the treatment of hereditary diseases such as epidermolysis bullosa. | Pharmaceuticals: Generic | Director/Board Member | |
MERUS N.V. | Biotechnology | Director/Board Member | |
GENSIGHT BIOLOGICS S.A. | Pharmaceuticals: Major | Director/Board Member | |
Opsona Therapeutics Ltd.
Opsona Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Opsona Therapeutics Ltd. operates as a immunology drug development company. It focuses on novel therapeutics and specializes in the prevention and treatment of solid organ transplantation, cancer, diabetes, autoimmune, inflammatory and Alzheimer’s diseases. The firm developed OPN-305, an antibody to reduce pro-inflammatory cytokine production, which is now at the clinical testing phase. The company was founded by Luke O'Neill, Kingston Mills and Dermot Kelleher in 2004 and is headquartered Dublin, Ireland. | Pharmaceuticals: Major | Director/Board Member | |
NESTLÉ S.A. | Food: Major Diversified | Corporate Officer/Principal | |
Anokion SA
Anokion SA Medical/Nursing ServicesHealth Services Anokion SA provides technology for retraining white blood cells to induce therapeutic immune tolerance. The firm?s approach to antigen-specific immune tolerance can be translated to virtually any protein in numerous clinical indications. The company was founded by Jerffery Hubbell, Melody Swartz, Stephan Kontos, Oscar Buset, Kristen M. Lorentz and David A. Lowin and is headquartered in Ecublens, Switzerland. | Medical/Nursing Services | Director/Board Member | |
Kanyos Bio, Inc.
Kanyos Bio, Inc. Pharmaceuticals: MajorHealth Technology Kanyos Bio, Inc. engages in the provision of immune tolerance technology solutions. It develops antigen-specific for treatment of type-1 diabetes and celiac disease. The company was founded by Jeffrey Hubbell, Stephan Kontos, Oscar Buset, Kristen M. Lorentz, and David A. Lowin in 2015 and is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Director/Board Member | |
Adicet Therapeutics, Inc.
Adicet Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Adicet Therapeutics, Inc. operates as a biopharmaceutical company focuses on the development of cell immunotherapies. It engages in the design and development of immunotherapies for cancer and other disease indications with a focus on novel universal immune cell therapies. The company was founded by Aya Jakobovits in 2014 and is headquartered in Beverly Hills, CA. | Pharmaceuticals: Major | Director/Board Member | |
Inflazome Ltd.
Inflazome Ltd. Pharmaceuticals: MajorHealth Technology Inflazome Ltd. engages in developing therapeutic medicines for inflammatory diseases. It manufactures and supplies medicines for muckle wells, type 2 diabetes, atherosclerosis, hypertension, gout, osteoarthritis, rheumatoid arthritis, Parkinson, Alzheimer, and multiple sclerosis. The company was founded by Matthew A. Cooper and Luke O'Neill in 2016 and is headquartered in Dublin, Ireland. | Pharmaceuticals: Major | Director/Board Member | |
Vivet Therapeutics SAS
Vivet Therapeutics SAS BiotechnologyHealth Technology Vivet Therapeutics SAS develops novel gene therapy treatments for inherited metabolic diseases. The firm offers its services under the categorizers of Biopharma, Biotechnology and Health Care. The company was founded by Jean-Philippe Combal, Gloria Gonzalez-Aseguinolaza and Jens Kurth on July 26, 2016 and is headquartered in Paris, France. | Biotechnology | Chairman | |
binx health, inc.
binx health, inc. Information Technology ServicesTechnology Services Binx Health, Inc. develops and provides in vitro point-of-care (POC) testing on diseases such as sexually transmitted infections, neonatal sepsis and hospital acquired infections. Its technology products include in diagnostic and immunoassay platform, rapid POC, and nucleic acid detection technology. The company was founded by John Clarkson in 2005 and is headquartered in Trowbridge, the United Kingdom. | Information Technology Services | Director/Board Member | |
Oculis SA
Oculis SA Miscellaneous Commercial ServicesCommercial Services Oculis SA focuses on ophthalmic drugs and novel drug delivery to the eye. The Oculis drug delivery platform consists of a novel technique to facilitate drug absorption to both anterior and posterior parts of the eye. The advantage is a drug delivery system where diseases of the posterior part of the eye can be treated with a simple topical application. The Oculis drug delivery platform allows diseases such as DME (diabetic macular edema) at the posterior part of the eye to be treated with a non-invasive topical application. The company was founded by Einar Stefansson and Thorsteinn Loftsson in 2003is headquartered in Pully, Switzerland. | Miscellaneous Commercial Services | Chairman | |
Priothera Ltd.
Priothera Ltd. BiotechnologyHealth Technology Priothera Ltd. engages in the development of orally delivered sphingosine-1-phosphate (S1P) receptor modulators for hematological malignancies. The company was founded by Florent Gros, Shaval Patel, and Brice Suire in 2020 and is headquartered in Dublin, Ireland. | Biotechnology | Chief Executive Officer | |
Ludwig-Maximilians-Universität München | College/University | Graduate Degree |
Statistics
International
Switzerland | 12 |
France | 9 |
United States | 8 |
United Kingdom | 6 |
Ireland | 4 |
Sectoral
Health Technology | 33 |
Consumer Services | 4 |
Commercial Services | 4 |
Health Services | 3 |
Electronic Technology | 2 |
Operational
Director/Board Member | 33 |
Corporate Officer/Principal | 5 |
Founder | 4 |
Chief Executive Officer | 4 |
Independent Dir/Board Member | 4 |
Most connected contacts
Insiders | |
---|---|
Florent Gros | 28 |
Anja Koenig | 19 |
- Stock Market
- Insiders
- Frances Wildhaber
- Company connections